Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhKGF-2 for superficial partial-thickness burn wounds
CTR20140592Phase 3Active
- Sponsor
- STA Pharmaceutical
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human keratinocyte growth factor-2 in superficial partial-thickness burn, sponsored by STA Pharmaceutical. Started Sep 2014; status: active.
02
Drugs
recombinant human keratinocyte growth factor-2
03
Conditions
superficial partial-thickness burn
Beyond the preview
Go deeper on CTR20140592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140592.